

$p < 0.003$). QoL was significantly better ($p = 0.0001$) than in the control group. There was no difference in the haematological parameters or 24-month overall survival for all stages [study 74% versus control 56% ($p = 0.174$)]; however, there was a trend for longer survival in the patients treated with *W. somnifera* root extract plus chemotherapy.

Interpretation. Addition of *W. somnifera* to chemotherapy could have a positive effect on fatigue and improve QoL in patients with breast cancer. The effectiveness and toxicity of chemotherapy were not altered. Thus further study with a large sample size, uniform tumour criteria, and risk stratified patients with breast cancer could help to validate our preliminary outcome.

Funding. RU grant of University Sains Malaysia (2009-02011).

The authors declared no conflicts of interest.

doi:10.1016/j.ejca.2012.02.031

AOS15 ASSESSMENT OF COGNITIVE FUNCTION IN PATIENTS WITH BREAST AND COLON CANCERS UNDERGOING CHEMOTHERAPY: RESULTS FROM AN EXPLORATORY PILOT STUDY

S. Poovaneswaran*, S.Y. Yeo, Z.L. Gwee, Z.H. Wong, H.H. Tan.
International Medical University, Negeri Sembilan, Malaysia

Background. Memory loss after chemotherapy is one of the most commonly reported post-treatment symptoms by patients with cancer. This deterioration in cognitive function, commonly referred to as chemobrain or chemofog, was largely unacknowledged by the medical community until in recent years. An exploratory pilot study was undertaken in Tuanku Jaafar Hospital, Negeri Sembilan, Malaysia. The aim in the study was to assess the effect of chemotherapy on cognitive function of patients with breast and colon cancers.

Methods. Ten patients with cancer (6 patients with breast cancer patients and 4 with colorectal cancer) who were receiving adjuvant chemotherapy (anthracycline and/or 5-fluorouracil) were assessed using the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) before the first cycle of chemotherapy and again after the third cycle.

Findings. There were mean reductions of 6.1% in MoCA and 5.3% in MMSE; no difference was noted between patients with breast and those with colorectal cancer.

Interpretation. The reductions in both the tests suggest that chemotherapy does have an impact on cognitive function, although it must be noted that the sample size was small. Based on the results of this exploratory pilot study, we aim to do a further larger scale, longer study to assess cognitive function after chemotherapy.

The authors declared no conflicts of interest.

doi:10.1016/j.ejca.2012.02.032

AOS16 CANCER CARE ISSUES DURING RECOVERY: OBSERVATIONS FROM INDIA

M.M. Nympha, B. Thomas*. Christ University, Bangalore, India

Background. Because of the lack of literature about patients with cancer in the Indian setting, increasing incidence of the disease, changing trends in treatment, and residual cancer or side-effects that restrict activities of daily living (bathing, eating, using the bathroom)

or functional disabilities (e.g. in walking, standing, or sitting), the care of people with cancer has been transferred to caregivers (Hewitt et al., 2003). Hence, in this study, the needs of caregivers were assessed to develop an organised programme for caregivers in the Indian setting.

Methods. Sixty caregivers were interviewed according to a schedule in a cross-sectional study. The patients receiving care had heterogeneous cancer diagnoses and were hospitalised for at least one month.

Findings. The highest need was financial followed by informational, family, personal, social, psychological, and spiritual needs by contrast with findings of the studies from the west where psychological need was the highest.

Interpretation. Changing trends in treatment have led to patients being discharged early from hospital. Consequently, there is a transition of care from hospital to family caregivers. Additionally, the residual cancer or side-effects of the disease that restrict activities of daily living (e.g. bathing and eating) or functional disabilities (e.g. difficulty in walking, standing, or sitting) or make the care recipients more dependent on the caregivers. Thus reduced hospitalisation and increased dependence of care recipients on the caregivers have resulted in increased care demands that in turn would affect the caregiver's needs.

The authors declared no conflicts of interest.

doi:10.1016/j.ejca.2012.02.033

AOS17 KRAS GENOTYPES IN THAI PATIENTS WITH COLORECTAL CANCER

P. Autkittanon^a, B. Reukumneuychok^b, N. Limsuwanachot^b, T. Ativitavas^a, T. Sirisinha^a, R. Panvichian^a, V. Ratanatharathorn^a, E. Sirachainan^{*a}. ^aDepartment of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ^bDepartment of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Background. The reported prevalence of *KRAS* mutations, the predictive factor of efficacy of cetuximab in colorectal cancer, varies in 30–40% of patients. However, the prevalence and correlations between *KRAS* mutation and clinical outcome in Thai patients have never been investigated. We did a retrospective study to define the *KRAS* genotype in Thai patients with colorectal cancer.

Methods. Genomic DNA from patients' paraffin-embedded tumour tissues was analysed for *KRAS* mutation at codons 12 and 13 by use of direct sequencing. Their clinical characteristics and outcomes were correlated with the genotype patterns. The concordance of *KRAS* genotype between primary tumour and available metastatic tumour was analysed

Findings. One hundred and seventeen patients with colorectal cancer were enrolled. Eighty-three patients (70.9%) had wild-type *KRAS* (WT-*KRAS*) whereas 34 patients (29.1%) had mutant *KRAS*. Gly12Asp (GGTGAT at codon 12) was the most common mutation (41.2%). The G13D mutation was detected in 14.7% of patients. Non-hepatic metastases were associated with mutant *KRAS* (adjusted OR = 3.699). The overall survival at 1, 2, and 5 years in patients with mutant *KRAS* was 85%, 75%, and 54%, respectively, compared with 96%, 83%, and 47%, respectively, in those with wild-type *KRAS* ($p = 0.56$). Discordance of the *KRAS* genotype (wild-type primary tumours and mutant metastatic tumours) was detected in 2 of 9 patients (22.2%). After cetuximab-chemotherapy, the PFS of one case with discordant *KRAS* was shorter than the median PFS in 10 cases with primary WT-*KRAS* (2.7 months versus 12.8 months).